Ovarian cancer is one of the most common malignant tumors of the female reproductive system. Globally, there are approximately 313,000 new cases each year, with around 88,000 new cases reported in China. About 70% of patients are diagnosed at an advanced stage, and over 80% experience recurrence within three years after initial treatment, resulting in an overall 5-year survival rate of less than 40%.
May 8 is World Ovarian Cancer Day. Let us join hands to focus on ovarian health. We encourage all women to stay alert to subtle physical changes, pursue scientific prevention and regular screening, and seek timely medical intervention. We also advocate for greater societal attention to ovarian cancer prevention and treatment, ensuring women have equitable access to standardized, high-quality healthcare services.
Surgery combined with platinum-based chemotherapy and targeted maintenance therapy currently serves as the primary treatment modality for ovarian cancer. However, almost all patients will eventually develop resistance to platinum-based chemotherapy, which remains the leading cause of mortality.
For patients with platinum-resistant ovarian cancer (PROC), the U.S. Food and Drug Administration (FDA) has approved several standard treatment options (such as trastuzumab deruxtecan and pembrolizumab plus chemotherapy, etc.), but most of these have not yet been approved in China. The current standard therapies in China remain non‑platinum chemotherapy with or without bevacizumab, as well as mirvetuximab soravtansine. However, the former has very limited efficacy (objective response rate of only about 10%–15%), while the latter is only indicated for patients with folate receptor alpha (FRα)-positive disease, which accounts for approximately 40% of PROC patients. There is an urgent clinical need for novel treatment modalities that can benefit a broader patient population and offer better efficacy.
In recent years, JSKN003, a novel HER2 bispecific antibody‑drug conjugate (ADC) independently developed by Alphamab Oncology, has brought new hope to this patient population, leveraging its unique technological innovation and clinical data demonstrating excellent efficacy and safety profile. Data presented by Professor Wu Xiaohua’s team from Fudan University Shanghai Cancer Center at the 2025 ASCO Annual Meeting and ESMO Congress showed combined results from JSKN003-101 and 102 trials: regardless of HER2 expression status or prior treatment with bevacizumab and PARP inhibitors, PROC patients achieved an objective response rate (ORR) of 63.0%, a median progression-free survival (mPFS) of 7.7 months, and a 9-month overall survival (OS) rate of 89.9%. In the JSKN003-102 study, patients with primary platinum-refractory ovarian cancer recorded an ORR of 32.0%, a disease control rate (DCR) of 72.0%, a median PFS of 4.1 months, and a 9-month OS rate of 65.4%.
JSKN003 has been granted Breakthrough Therapy Designation (BTD) by China’s Center for Drug Evaluation (CDE) for all-comer PROC. It has also received BTD from the FDA for HER2-expressing PROC patients previously treated with bevacizumab. The Phase III clinical study of JSKN003 for the treatment of all-comer PROC is currently progressing smoothly in China.
Every medical innovation and clinical advancement breaks the shackles of disease, embodying our commitment to safeguarding patients’ love, dignity and hope. Empowered by innovation, we stand with women in need, helping them shine bright and be the fearless leading ladies of their own lives.
About Alphamab Oncology
Alphamab Oncology (Stock Code: 9966.HK) is an innovative biopharmaceutical company focused on oncology. Leveraging proprietary platforms-including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payloads, dual-payload ADCs, and high-concentration subcutaneous formulations, the Company has built a differentiated and globally competitive pipeline, covering cutting-edge candidates in ADCs, bispecific antibodies, and single-domain antibodies.
One product has received market approval: Envafolimab (KN035, brand name: 恩维达®), the world's first subcutaneously injected PD-(L)1 inhibitor, offering greater convenience and accessibility in cancer treatment. The NMPA has accepted the new drug application for KN026 (Anbenitamab Injection), a HER2 bispecific antibody, for second-line or later HER2-positive gastric cancer, and currently under review. Five bispecific ADC candidates have entered clinical stages, and next-generation ADC pipelines—such as dual-payload ADCs—are advancing rapidly. The Company has established strategic partnerships with organizations including CSPC, ArriVent, and Glenmark, covering both product development and technology platforms.
Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, enabling patients to achieve long-term, high-quality survival and delivering China-innovated cancer therapies to benefit patients worldwide.
Alphamab Oncology Forward-Looking Statements
This press release contains statements related to our future business，financial performance and future events involving Alphamab Oncology that may constitute forward-looking statements. These statements include projections and estimates and relevant assumptions, statements regarding plans and expectations and statements regarding future activities, operations and performance. These statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," or words of similar meaning. Such statements are based on the certain assumptions of Alphamab Oncology’s management and business operations, which are subject to various risks and uncertainties, including but not limited to political, economic, legal and business environment. The actual results, performance or achievements of Alphamab Oncology may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statements. Unless otherwise required by applicable laws, Alphamab Oncology does not undertake obligation to publicly update any forward-looking statement nor liability for the failure to materialize such forward-looking statements, whether because of new information, future events or otherwise.
Pharmaceutical Information Statements
Alphamab Oncology does not recommend the clinical use of any already approved or under-development drugs/indications. Any information contained in this press release should not be regarded as any drug application, promotion or advertisement.
